HC Wainwright Lifts Earnings Estimates for Coya Therapeutics

Coya Therapeutics, Inc. (NASDAQ:COYA) – Equities researchers at HC Wainwright boosted their Q3 2026 EPS estimates for shares of Coya Therapeutics in a research report issued to clients and investors on Monday, August 24th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.33) per share for the quarter, up from their prior estimate of ($0.40). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Coya Therapeutics’ current full-year earnings is ($1.44) per share. HC Wainwright also issued estimates for Coya Therapeutics’ Q4 2026 earnings at ($0.36) EPS, FY2026 earnings at ($1.30) EPS, Q1 2027 earnings at ($0.44) EPS, Q2 2027 earnings at ($0.48) EPS, Q3 2027 earnings at ($0.40) EPS, Q4 2027 earnings at ($0.33) EPS and FY2027 earnings at ($1.64) EPS.

Coya Therapeutics (NASDAQ:COYA) last released its earnings results on Tuesday, August 11th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.07. The company had revenue of $0.24 million during the quarter, compared to the consensus estimate of $0.13 million. Coya Therapeutics had a negative return on equity of 52.05% and a negative net margin of 270.22%.

A number of other equities analysts have also weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Friday, July 17th. Chardan Capital reaffirmed a “buy” rating and issued a $14.00 target price on shares of Coya Therapeutics in a research note on Wednesday, August 12th. Roth Capital reiterated a “buy” rating and issued a $12.00 price target on shares of Coya Therapeutics in a report on Monday. Finally, Wall Street Zen lowered Coya Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $15.33.

Coya Therapeutics Trading Up 1.6%

Shares of NASDAQ COYA opened at $5.04 on Wednesday. The stock has a market cap of $118.24 million, a price-to-earnings ratio of -4.71 and a beta of 0.60. Coya Therapeutics has a 52 week low of $3.71 and a 52 week high of $7.75. The company’s 50-day moving average price is $4.90 and its 200 day moving average price is $4.68.

Institutional Trading of Coya Therapeutics

Several large investors have recently bought and sold shares of the company. Alyeska Investment Group L.P. bought a new stake in shares of Coya Therapeutics in the fourth quarter worth $4,640,000. AWM Investment Company Inc. bought a new position in Coya Therapeutics during the 4th quarter valued at $4,205,000. CM Management LLC boosted its stake in Coya Therapeutics by 16.7% during the 4th quarter. CM Management LLC now owns 350,000 shares of the company’s stock valued at $2,030,000 after acquiring an additional 50,000 shares during the last quarter. Private Management Group Inc. acquired a new position in Coya Therapeutics during the 4th quarter worth $1,626,000. Finally, Marshall Wace LLP increased its position in shares of Coya Therapeutics by 438.8% in the 4th quarter. Marshall Wace LLP now owns 225,358 shares of the company’s stock worth $1,307,000 after purchasing an additional 183,533 shares during the last quarter. Institutional investors and hedge funds own 39.75% of the company’s stock.

Coya Therapeutics News Summary

Here are the key news stories impacting Coya Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained a “Buy” rating and raised its FY2026 EPS forecast to a loss of $1.30 from a prior loss of $1.52. The firm also improved its Q3 2026 estimate to a loss of $0.33 from $0.40 and lifted its Q4 2026 forecast to a loss of $0.36 from $0.44. HC Wainwright estimates
• Positive Sentiment: The analyst raised its FY2027 EPS outlook to a loss of $1.64 from $1.66, while improving its Q1 2027 and Q4 2027 forecasts. Although the company is still expected to report losses, the revisions imply a modestly better profitability trajectory. HC Wainwright earnings revisions
• Positive Sentiment: Roth Capital reaffirmed its “Buy” rating and set a $12.00 price target, substantially above the referenced $5.04 share price. Analysts overall assigned Coya an average target of $15.33, indicating significant perceived upside if the company executes on its development plans. Coya Therapeutics earns Buy rating from Roth Capital Coya Therapeutics average analyst price target
• Neutral Sentiment: HC Wainwright lowered its Q2 2027 EPS estimate to a loss of $0.48 from $0.46 and its Q3 2027 estimate to a loss of $0.40 from $0.39. These reductions partially offset the more favorable revisions elsewhere.
• Neutral Sentiment: Reported short interest was zero shares, leaving no meaningful short-covering or short-squeeze signal. Coya’s small market capitalization and continuing losses remain important risks despite the bullish ratings.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.